A randomized controlled trial on adults who underwent orthopedic surgery. To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing SSIs in the orthopedic surgical population.
Eligible patients will be randomized in a block design into 2 groups: intervention and control. The intervention group will use continuous infusion of cefazolin (CI), while the control group will follow the traditional presurgical prophylaxis protocol of intermittent cefazolin doses (INT).
Orthopaedic surgical ward patients who underwent major surgery.
Patients who require reoperation within 30 days.
Immunosuppressant patients.
Patients who are not adherent to the protocol time or dosing, either preoperatively, during, or postoperatively.
Pregnancy or breastfeeding.
Parallel
Cefazolin 2 g Infusion
DrugIntraoperative continuous infusion (CI) of cefazolin
Cefazolin 2 GM Injection
DrugAdministration of cefazolin 2 gm 30 minutes pre-surgery
Incidence of surgical site infection
To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing SSIs in the orthopedic surgical population.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
